Literature DB >> 11159797

Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.

L M Hesse1, L L von Moltke, R I Shader, D J Greenblatt.   

Abstract

Since antiretroviral drugs are known to inhibit many cytochrome P450 isoforms, the inhibition of CYP2B6 by non-nucleoside reverse transcriptase inhibitors and viral protease inhibitors was studied in vitro in human liver microsomes using bupropion hydroxylation as the CYP2B6 index reaction. Mean IC(50) values (microM) for inhibition of bupropion hydroxylation were: nelfinavir (2.5), ritonavir (2.2), and efavirenz (5.5). The reaction was only weakly inhibited by indinavir, saquinavir, amprenavir, delavirdine, and nevirapine. The inhibition of bupropion hydroxylation in vitro by nelfinavir, ritonavir, and efavirenz indicates inhibitory potency versus CYP2B6 and suggests the potential for clinical drug interactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159797

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  33 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine.

Authors:  Devinder Sharma; Aik Jiang Lau; Matthew A Sherman; Thomas K H Chang
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

3.  Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

Authors:  Ari S Nowacek; JoEllyn McMillan; Reagan Miller; Alec Anderson; Barrett Rabinow; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2010-03-17       Impact factor: 4.147

Review 4.  Drug treatment of depression in HIV-positive patients : safety considerations.

Authors:  Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  In vitro cytochrome P450-mediated metabolism of exemestane.

Authors:  Landry K Kamdem; David A Flockhart; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-09-28       Impact factor: 3.922

Review 6.  Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.

Authors:  Crystal C Watkins; Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

7.  Identifying and managing depression in the medical patient.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

8.  In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.

Authors:  Cong Xu; Zeruesenay Desta
Journal:  Drug Metab Pharmacokinet       Date:  2013-02-05       Impact factor: 3.614

Review 9.  Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.

Authors:  John F Deeken; Liron Pantanowitz; Bruce J Dezube
Journal:  Curr Opin Oncol       Date:  2009-09       Impact factor: 3.645

10.  Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.

Authors:  Evan D Kharasch; Darain Mitchell; Rebecka Coles; Roberto Blanco
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.